As we prepare to enter the next decade of this revolutionary law, we cordially invite you to join us for ACI’s 11th Annual Biosimilars Summit.
As the number of FDA-approved biosimilar products continues to grow,the need for a solid guiding framework becomes more critical than ever before. While the stakeholders wait for finality on the rules governing significant matters like interchangeability, substitution and equivalency, it is clear that biosimilars will remain a top priority for the FDA.
The biosimilars market continues to maintain momentum as we head into 2020, but questions remain as to whether the U.S. market will catch up with Europe and whether biosimilars will provide their intended cost-savings.
Join the “who’s who” of the biosimilars and innovator biologics industries as they gather in New York for ACI’s 2020 Summit on Biosimilars, and contemplate these and other probing questions.
Sign up and stay tuned for more exciting programming announcement and our incredible speaker line-up!
Thank You to Our Esteemed 2019 Biosimilars Co-Chairs
Immac “Casey” Thampoe
Executive Director/Assistant General Counsel
IP Portfolio Development
Regeneron Pharmaceuticals, Inc.
Year after year, the ACI Biosimilar Conference has featured a top-notch faculty from the pharma/biotech industry, private practice and government to address hot-button issues in this rapidly evolving area — I am looking forward to another outstanding event.
Charles K. Sholtz
Director and Associate General Counsel
Biosimilars, Manufacturing & Litigation Readiness Lead
If I had to pick only one event to get the latest on issues impacting biosimilars, it would be the ACI Biosimilar Conference — highly informative presentations and ample opportunities to network and catch-up with players in this space.
SAMPLE PAST IN-HOUSE ATTENDANCE
Bausch & Lomb Inc
Baxter Healthcare Corp
Ben Venue Laboratories
Boehringer Ingelheim GmbH
BRM Biopharm Source LLC
Cerulean Pharma Inc
Coherus Biosciences Inc
Daiichi Sankyo Co
Dr. Reddy’s Laboratories
Elan Pharmaceuticals Inc
Eli Lilly & Company
EMD Serono Inc
Endo Pharmaceuticals Inc
Fresenius Kabi USA
Fresenius Kabi Deutschland GmbH
Gan & Lee Pharmaceuticals
Gedeon Richter Pharma GmbH
Gene Techno Science Co
GTC Biotherapeutics Inc
ImClone Systems Incorporated
Johnson & Johnson
Kashiv Biosciences LLC
LG Life Sciences
Lupin Pharmaceuticals Inc
MedImmune Inc AstraZeneca
Merck & Co
Mitsubishi Tanabe Pharma Development America
PDL Biopharma Inc
Purdue Pharma LP
R-T Specialty LLC
Samsung Bioepis Co Ltd
Seattle Genetics Inc.
Shanghai Henlius Biotech Inc
Shionogi & Co Ltd
Sunovion Pharmaceuticals Inc
Sutro Biopharma Inc
Turnstone Biologics Inc
Vertical Pharmaceuticals Inc
Zydus Research Centre
Don’t miss this opportunity to benchmark your biosimilar strategies with top industry representatives.
Register now and enjoy early bird savings!
WHO YOU WILL MEET:
- In-house counsel from branded and biosimilars companies
- Government representatives from the FDA, USPTO, and the Judiciary
- Leading regulatory and patent attorneys from around the country
ACI’s Global Series of Life Sciences conferences bring together key sector stakeholders from around the globe to explore the most important trends impacting the many industries including pharmaceutical, biotechnology, medical device/diagnostics, and FDA-regulated consumer products. Our events cover every facet of legal and business relevance as well as controversy.